Stroke in woman is a high priority issue for the World Stroke Organization (WSO) and this journal. The WSO ongoing campaign ''I am woman'' underlines the importance of gender issues in stroke research and management. The study in our current edition from Arnao et al. nicely puts together the incidence, prevalence, and mortality for woman world wide from a perspective of the epidemiological transition theory of countries as they move from emerging, through to industrialized states. Data were somewhat limited in the emerging countries; incidence is increasing in stage 3 industrialized countries but tending to decrease in stage 4. Clearly, the gathering of more epidemiological data in emerging economies must be a priority, and continued, high-quality monitoring needs to occur in developed countries.
One of the most important recent developments in stroke management is the emergence of practical implantable cardiac devices to enable long-term monitoring. Perhaps, almost as expected, a number of studies have shown vastly improved detection rates for cardiac arrhythmias particularly with atrial fibrillation (AF). The question remains as to what this really means in terms of clinical outcomes. Much more work will need to be done to inform us about management strategies to relate the number, and duration of transient episodes of AF with the risk of stroke. We have a protocol from Italy by Danilo et al. aimed at gaining a better understanding of the usefulness of these devices and should provide data to contribute to the uncertainties mentioned earlier. Our paper by Diamantopoulos et al. shows that insertable cardiac monitors to detect AF in patients with cryptogenic stroke are cost effective.
A related surge in interest is in cryptogenic stroke, the mechanism which most of us believe to be cardio embolic; hence, the commencement of a number of trials of therapy in this population group to determine as to whether the noval oral anticoagulants (NOACS) might reduce current stroke risk. They are an obvious choice given their low hemorrhagic risk profile and ease of administration.
Even more progress in stroke prevention!
